A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GBT-440 | GBT-440 is a substituted benzaldehyde compound that can modulate sickle hemoglobin (HbS) for treatment of disorders. Uses: Hematologic agents. Synonyms: Voxelotor, GBT-440, GBT 440, GBT440, GTx-011, GTx011, GTx 011; 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde; Hemoglobin Modulators-1. Grade: >98%. CAS No. 1446321-46-5. Molecular formula: C19H19N3O3. Mole weight: 337.37. |  |
| GBT 440 hydrochloride | GBT 440 hydrochloride is an oral medication used to treat sickle cell disease in patients aged 12 and older. It functions by increasing hemoglobin's affinity for oxygen, which helps prevent red blood cell sickling and reduces associated complications. GBT 440 hydrochloride is a hemoglobin S (HbS) polymerization inhibitor. It binds to hemoglobin, stabilizing the hemoglobin molecule in its oxygenated form. This prevents the sickling of red blood cells and reduces the associated hemolysis and vaso-occlusive events. Synonyms: 2-Hydroxy-6-{[2-(1-isopropyl-1H-pyrazol-5-yl)-3-pyridinyl]methoxy}benzaldehyde hydrochloride (1:1); Benzaldehyde, 2-hydroxy-6-[[2-[1-(1-methylethyl)-1H-pyrazol-5-yl]-3-pyridinyl]methoxy]-, hydrochloride (1:1); 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde hydrochloride; GBT-440 hydrochloride; GBT440 hydrochloride; Voxelotor hydrochloride; Oxbryta hydrochloride; Hemoglobin Modulators-1 hydrochloride. Grade: ≥95%. CAS No. 1667717-41-0. Molecular formula: C19H20ClN3O3. Mole weight: 373.84. | |
| GC 14 | GC 14 is a selective antagonist of thyroid hormone receptor (THR), with IC50s of 35 and 200 nM for hTRβ and hTRα, respectively. Synonyms: Thyromimetic, 5a; {4-[(6-Hydroxy-5-isopropyl-4'-nitro-3-biphenylyl)methyl]-3,5-dimethylphenoxy}acetic acid; Acetic acid, 2-[4-[[6-hydroxy-5-(1-methylethyl)-4'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-. Grade: ≥95%. CAS No. 447415-34-1. Molecular formula: C26H27NO6. Mole weight: 449.50. | |
| GC376 | GC376 Inhibitor. Uses: Scientific use. Product Category: T5188. CAS No. 1416992-39-6. |  |
| GC376 sodium | GC376 sodium is a 3CLpro inhibitor; inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1416992-39-6. Pack Sizes: 25 mg; 50 mg; 100 mg. Product ID: HY-100721. |  |
| GC376 sodium | GC376 is a 3CLpro inhibitor which is previously reported to be active against the 3CLpro of multiple coronaviruses, including SARS-CoV, but with highest potency against FIPV in cell culture. GC376 inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM. Synonyms: GC376 sodium; GC 376 sodium; GC-376 sodium; (2S)-1-hydroxy-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate sodium. Grade: ≥98% (HPLC). CAS No. 1416992-39-6. Molecular formula: C21H30N3NaO8S. Mole weight: 507.53. | |
| GC7 Sulfate | GC7 Sulfate is an inhibitor of deoxyhypusine synthase (DHPS). Synonyms: N1-guanyl-1,7-diaminoheptane Sulfate; GC 7 Sulfate; GC-7 Sulfate. CAS No. 150417-90-6. Molecular formula: C8H22N4O4S. Mole weight: 270.35. | |
| GC7 Sulfate | GC7 Sulfate is a deoxyhypusine synthase (DHPS) inhibitor. Uses: Scientific research. Category: Signaling pathways. CAS No. 150417-90-6. Pack Sizes: 10 mM * 1 mL in Water; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108314A. | |
| Gcase activator 2 | Gcase activator 2 (compound 14), a pyrrolo[2,3-b]pyrazine, is alos a β-Glucocerebrosidase (GCase) activator (EC50=3.8 μM). Gcase activator 2 induces GCase dimerizatio (both K-type and V-type). And Gcase activator 2 has low metabolic clearance in human and mouse[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2759897-35-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-154823. | |
| Gcase activator 3 | Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2270984-21-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-160426. | |
| GCB Graphitized Carbon Black | GCB Graphitized Carbon Black. CAS No. 7440-44-0. Product ID: ACM7440440-197. Mole weight: 12.011g/mol. IUPAC Name: carbon. ECNumber: 231-153-3;215-609-9;231-953-2;231-955-3;240-383-3;231-153-3;264-846-4;603-226-3;612-159-9;619-291-6. Alfa Chemistry - ISO 9001:32057 Certified. |  |
| GCB Graphitized Carbon Black | Carbon black oil appears as a dark colored liquid with a petroleum-like odor. Less dense than water and insoluble in water. Vapors heavier than air.;Carbon, activated is a black grains that have been treated to improve absorptive ability. May heat spontaneously if not properly cooled after manufacture.;Carbon, animal or vegetable origin appears as a black powder or granular mixed with a tar or starch and water binder pressed into regular lumps or briquettes. Heats slowly and ignites in air especially if wet.;Graphite (natural) appears as a mineral form of the element carbon. Hexagonal crystals or thin leaf-like layers. Steel-gray to black with a metallic luster and a greasy feel. An electrical conductor. Used for high-temperature crucibles, as a lubricant and in "lead" pencils.;DryPowder; DryPowder, Liquid; DryPowder, PelletsLargeCrystals; DryPowder, PelletsLargeCrystals, WetSolid, OtherSolid, Liquid; DryPowder, WetSolid, Liquid; Liquid; OtherSolid; OtherSolid, GasVapor, Liquid; PelletsLargeCrystals; PelletsLargeCrystals, OtherSolid, Liquid; WetSolid; WetSolid, Liquid;OtherSolid; PelletsLargeCrystals;DryPowder; DryPowder, OtherSolid; DryPowder, PelletsLargeCrystals; OtherSolid; PelletsLargeCrystals; PelletsLargeCrystals, OtherSolid; WetSolid;DryPowder; DryPowder, OtherSolid; DryPowder, PelletsLargeCrystals; DryPowder, WetSolid; Liquid; OtherSolid; PelletsLargeCrystals; PelletsLargeCrystals, OtherSolid; WetSol |  |
| G(Cbz)-acetic acid | G(Cbz)-acetic acid. CAS No. 169287-69-8. Molecular formula: C15H13N5O5. Mole weight: 343.29. | |
| GC Enhancer | GC Enhancer. Gc enhancer should be used with dna ploymerase to optimize pcr from complex templates including gc rich. the storage concentration is 10×. the working concentration can adjust between 0.5×-5×. Group: Cloning Enzymes. Purity: 200ul. Storage: Store at -20 ?. Cat No: CE-3007. |  |
| Gc-globulin from human plasma | Gc-globulin from human plasma. Uses: For analytical and research use. CAS No. 68476-36-8. Catalog: AP68476368-A. |  |
| GcLEAP-2 | GcLEAP-2 is isolated from tenopharyngodon idella [Grass carp] and has antimicrobial activity. | |
| GCN2 activator-1 | GCN2 activator-1 (Compound 20) is a GCN2 activator. GCN2 activator-1 binds within the ATP-pocket of GCN2 and activates GCN2 in a GCN1-independent manner. GCN2 activator-1 activates Integrated Stress Response (ISR) in cells. GCN2 activator-1 inhibits PKR with an IC50 of 3.75 μM. GCN2 activator-1 can be used for research of pulmonary veno-occlusive disease (PVOD)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 315705-10-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-W319647. | |
| GCN2iB | GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2183470-12-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112654. | |
| GCN2iB | GCN2iB is an ATP-competitive inhibitor of serine/threonine-protein kinase general control nonderepressible 2 (GCN2) with IC50 of 2.4 nM. Synonyms: N-[3-[2-(2-Amino-5-pyrimidinyl)ethynyl]-2,4-difluorophenyl]-5-chloro-2-methoxy-3-pyridinesulfonamide. CAS No. 2183470-12-2. Molecular formula: C18H12ClF2N5O3S. Mole weight: 451.83. | |
| GCN2-IN-1 | GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1448693-69-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg; 1 g. Product ID: HY-100877. | |
| GCN2-IN-6 | GCN2-IN-6 is a potent and orally available inhibitor of GCN2 confirmed by in-house enzymatic (IC50 = 1.8 nM) and cellular assays (IC50 = 9.3 nM). It is also an eIF2α kinase PERK inhibitor with IC50s of 0.26 nM and 230 nM in enzymatic assay and in cells, respectively. Synonyms: Benzenesulfonamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]-2,4-difluorophenyl]-2,5-dichloro-3-(hydroxymethyl)-; N-{3-[(2-aminopyrimidin-5-yl)ethynyl]-2,4-difluorophenyl}-2,5-dichloro-3-(hydroxymethyl)benzene-1-sulfonamide. Grade: ≥97%. CAS No. 2183470-09-7. Molecular formula: C19H12Cl2F2N4O3S. Mole weight: 485.29. | |
| GCN2-IN-6 | GCN2-IN-6 (Compound 6d) is a potent, and orally available GCN2 inhibitor confirmed by in-house enzymatic (IC50 of 1.8 nM) and cellular assays (IC50 of 9.3 nM). GCN2-IN-6 is also a eIF2α kinase PERK inhibitor with an IC50 of 0.26 nM (in enzymatic assay) and 230 nM (in cells)[1]. GCN2-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 2183470-09-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-130240. | |
| GCN2-IN-7 | GCN2-IN-7 (compound 39) is an orally active and selective general control nonderepressible 2 (GCN2) inhibitor (IC50=5 nM). GCN2-IN-7 shows anti-tumor activity in vivo[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2396465-33-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-151460. | |
| GD1b-Ganglioside | GD1b-Ganglioside is a pivotal biomolecule, finding widespread application for the comprehensive investigation and comprehension of diverse neurodegenerative ailments, including Parkinson's disease is alzheimer's disease and Multiple Sclerosis. Synonyms: Ganglioside GD1b; Ganglioside C1; Ganglioside G2; Ganglioside G2 (hexasaccharide); Ganglioside GIII; GD1b; GD1b ganglioside. CAS No. 19553-76-5. Molecular formula: C80H144N4O37. Mole weight: 1754. | |
| GD1b-Oligosaccharide | GD1b-Oligosaccharide is a crucial component widely used in the research of neurological diseases, including Alzheimer's and Parkinson's. With its bioactive properties, GD1b-Oligosaccharide holds promise for targeted drug delivery systems, disease diagnostics and advanced research in neurobiology. Synonyms: Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glc. Molecular formula: C48H77N3O37Na2. Mole weight: 1334.10. | |
| GD2-Ganglioside | GD2-Ganglioside is a complex lipid molecule extensively present within the neuroblastoma tumours cells. This molecule is the focal point of numerous immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy and monoclonal antibodies and has the ability to specifically recognize and demolish GD2-Ganglioside expressing cancer cells. Synonyms: Ganglioside GD2; Disialoganglioside-GD2; Disialoganglioside GD2; GD2. CAS No. 65988-71-8. | |
| GD2-GANGLIOSIDE | GD2-GANGLIOSIDE. CAS No. 65988-71-8. Purity: 95%. Product ID: ACM65988718. Molecular formula: C74H134N4O32. Mole weight: 1591.86. Alfa Chemistry - ISO 9001:32057 Certified. | |
| Gd2O3 nanopowder | Gd2O3 nanopowder. Purity: 99.9% (REO). | |
| GD2-Oligosaccharide | GD2-Oligosaccharide is a biomedical product used in the research of neuroblastoma. It has been found to target the GD2 antigen present on neuroblastoma cells. Synonyms: GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc. Molecular formula: C42H67N3O32Na2. Mole weight: 1171.96. | |
| GD2-Oligosaccharide-b-(N-acetyl-propargyl) | GD2-Oligosaccharide-b-(N-acetyl-propargyl) is a remarkable biomedical compound, emerging as a formidable compound in the research of neuroblastoma, an affliction predominantly encountered during early stages of life. Synonyms: GD2-Saccharide-b-NAc-propargyl. Molecular formula: C47H72N4O32Na2. Mole weight: 1251.06. | |
| GD2-Oligosaccharide-desthiobiotin | GD2-Oligosaccharide-desthiobiotin is a compound product used in the research of GD2-positive cancers, composed of desthiobiotin and GD2 oligosaccharide. It specifically targets GD2 receptors on cancer cells. Molecular formula: C65H106N10O37.2Na. Mole weight: 1665.56. | |
| GD2-Oligosaccharide-sp-biotin | GD2-Oligosaccharide-sp-biotin is a powerful tool used for researching various diseases such as neuroblastoma, melanoma and certain other cancers. It specifically targets GD2 oligosaccharide. The addition of biotin enables efficient detection and purification of GD2 oligosaccharide in experimental settings. Molecular formula: C65H104N10O37SNa2. Mole weight: 1695.61. | |
| GD3-Ganglioside | GD3-Ganglioside, a glycosphingolipid, is an intricate modulator of cell growth, differentiation and apoptosis. Anti-cancer therapies utilizing GD3-Ganglioside as a therapeutic target have shown significant promise, making it a distinguished focus of research in the realm of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. In addition to the fascinating roles delineated above, GD3-Ganglioside has been extensively studied for its potential as an antiviral agent owing to its involvement in the immune response. Synonyms: Ganglioside GD3; Disialohematoside; Disialohematoside GD3; Disialosyllactosylceramide; Ganglioside D3; GD3. CAS No. 62010-37-1. | |
| GD3-Ganglioside, biotin labelled | GD3-Ganglioside, biotin labelled. | |
| GDC-0068 dihydrochloride | Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69 nM, and 860 nM, respectively). GDC-0068 displays >100-fold selectivity for Akt over PKA with IC50 of 3.1 μM. In LNCaP, PC3 and BT474M1 cells, GDC-0068 treatment inhibits the phosphorylation of the Akt substrate, PRAS40 with IC50 of 157 nM, 197 nM, and 208 nM, respectively. Furthermore, GDC-0068 selectively inhibits cell cycle progression and viability of cancer cell lines driven by Akt signaling, including those with defects in the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2, with strongest effects in HER2+ and Luminal subtypes. Oral administration of GDC-0068 in PC3 prostate tumor xenografts model induces down-regulation of p-PRAS40. In BT474-Tr xenografts, GDC-0068 treatment reduces pS6 and peIF4G levels, re-localizes FOXO3a to nucleus, and induces feedback upregulation of HER3 and pERK. Administration of GDC-0068 exhibits potent antitumor efficacy in multiple xenograft tumor models, including the PTEN-deficient prostate cancer models LNCaP and PC3, the PIK3CA H1047R mutant breast cancer model KPL-4, and MCF7-neo/HER2 tumor model. Synonyms: Ipatasertib dihydrochloride; RG-7440 dihydrochloride; GDC-0068 dihydrochloride; RG 7440 dihydrochloride; GDC 0068 dihydrochloride; RG7440 dihydrochloride; GDC0068 | |
| GDC-0077 | GDC-0077 is an orally available and selective PI3K inhibitor (IC50 = 0.038 + 0.003 nM) with > 300-fold selective over other Class I PI3K isoforms. GDC-0077 exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Synonyms: GDC 0077; GDC0077; Inavolisib. CAS No. 2060571-02-8. Molecular formula: C18H19F2N5O4. Mole weight: 407.37. | |
| GDC-0077 (Inavolisib) | Inavolisib (GDC-0077, RG6114, RO-7113755) is a potent selective inhibitor of PI3K alpha (PI3Kα) with an IC50 of 0.038 nM. GDC-0077 is >300-fold more selective for PI3K alpha over the other class I PI3K isoforms (beta, delta, and gamma) and >2000-fold more selective over PIK family members. GDC-0077 binds to the ATP binding site of PI3K and inhibits the phosphorylation of PIP2 to PIP3. Group: Inhibitors. Alternative Names: RG6114, RO-7113755. CAS No. 2060571-02-8. Pack Sizes: 5mg. Product ID: S8668. Formula: C18H19F2N5O4. Smiles: CC(C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4C(COC4=O)C(F)F. Storage Conditions: 3 years -20°C powder. |  United States; Europe |
| GDC-0084 | GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just licensed to Novogen and start a Phase II trial for Glioma. Uses: Gdc-0084 is a pi3k inhibitor that has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. Synonyms: RG7666; RG-7666; RG 7666; GDC-0084; GDC0084; GDC 0084; 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine. Grade: 98%. CAS No. 1382979-44-3. Molecular formula: C18H22N8O2. Mole weight: 382.19. | |
| GDC-0152 | GDC-0152 is a second mitochondrial activator of caspases (Smac) mimetic inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0152 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2, which may inhibit their activities and promote the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Smac, the endogenous IAP antagonist, relies on its N-terminal four amino-acid motif for binding to IAPs. Synonyms: GDC-0152; GDC0152; GDC 0152. CAS No. 873652-48-3. Molecular formula: C25H34N6O3S. Mole weight: 498.646. | |
| GDC-0152 | GDC-0152 is a potent IAPs inhibitor, and binds to the BIR3 domains of XIAP, cIAP1, cIAP2 and the BIR domain of ML-IAP with Ki values of 28 nM, 17 nM, 43 nM and 14 nM, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 873652-48-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13638. | |
| GDC-0214 | GDC-0214 is a highly potent, selective and inhalable Janus kinase-1 (JAK-1) inhibitor. Synonyms: GDC 0214; GDC0214; iJak-381; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide. CAS No. 1831144-46-7. Molecular formula: C28H28ClF2N9O3. Mole weight: 612.04. | |
| GDC-0276 | GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC50 value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1494581-70-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-114237. | |
| GDC-0310 | GDC-0310 is a selective acyl-sulfonamide Nav1.7 inhibitor, with an IC50 of 0.6 nM for hNav1.7[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1788063-52-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139081. | |
| GDC-0310 | Nav1.7 is an extensively investigated target for pain. GDC-0310 is a selective Nav1.7 inhibitor. Synonyms: UNII-72GO7NL642; GDC 0310. CAS No. 1788063-52-4. Molecular formula: C25H29Cl2FN2O4S. Mole weight: 543.48. | |
| GDC-0326 | GDC-0326 is a potent and selective PI3Kα inhibitor with a Ki of 0.2 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1282514-88-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-101272. | |
| GDC-0326 | GDC-0326 is a selective PI3Kα (α-Isoform of Phosphoinositide 3-Kinase) inhibitor. GDC-0326 is highly selective over other kinases. It has low plasma CL in human. In PI3 kinase family, there are four class I PI3K isoforms including α, β, δ, and γ and PI3Kα is the most commonly associated with cancers, so GDC-0326 may become a drug candidate for cancer treatment. Uses: Anti-cancer. Synonyms: GDC-0326; GDC 0326; GDC0326; (S)-2-((2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide. Grade: 98%. CAS No. 1282514-88-8. Molecular formula: C19H22N6O3. Mole weight: 382.42. | |
| GDC-0334 | GDC-0334, a TRPA1 antagonist, is used for the treatment of TRPA1-mediated diseases, such as pain or asthma. Synonyms: (4R,5S)-4-fluoro-1-[(4-fluorophenyl)sulfonyl]-5-methyl-N-({5-(trifluoromethyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl}methyl)-L-prolinamide; 2-Pyrrolidinecarboxamide, 4-fluoro-1-[(4-fluorophenyl)sulfonyl]-5-methyl-N-[[5-(trifluoromethyl)-2-[2-(trifluoromethyl)-5-pyrimidinyl]-4-pyridinyl]methyl]-, (2S,4R,5S)-. Grade: ≥90%. CAS No. 1984824-54-5. Molecular formula: C24H19F8N5O3S. Mole weight: 609.49. | |
| GDC-0339 | GDC-0339, also called as SCHEMBL14801965, is a selective inhibitor of BaF3 PIM1 that has the potential for treatment of cancer. BaF3 PIM1: IC50= 43.6 nM; PIM1 LC-3K: IC50= 0.04 nM. Synonyms: 5-amino-N-[5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methylpyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamideGDC-0339; GDC 0339; GDC0339; SCHEMBL14801965BDBM110706CS-4775; HY-16976; CS 4775; HY 16976; CS4775; HY16976; US8614206, 139. CAS No. 1428569-85-0. Molecular formula: C20H22F3N7OS. Mole weight: 465.50. | |
| GDC-0339 | GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1428569-85-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-16976. | |
| GDC-0349 | GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma. Synonyms: GDC-0349; GDC 0349; GDC0349; RG7603. CAS No. 1207360-89-1. Molecular formula: C24H32N6O3. Mole weight: 452.559. | |
| GDC-0425 | This active molecular is an selective Checkpoint kinase 1 (Chk1) inhibitors and it enhances gemcitabine efficacy in tumor xenograft models. GDC-0425 was safe and yielded responses in patients with a variety of cancers. In Oct 2013, GDC 0425 was in phase I trials for Solid tumours and Lymphoma (late-stage disease) in USA and France. In May 2014, Genentech completed a phase I trial in Lymphoma and Solid tumours (late-stage disease) in USA and France. Uses: Solid tumours and lymphoma. Synonyms: GDC-0425; GDC 0425; GDC0425; 5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile; RG-7602; RG 7602; RG7602. Grade: 98%. CAS No. 1200129-48-1. Molecular formula: C18H19N5O. Mole weight: 321.38. | |
| GDC046 | GDC046 is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively. Synonyms: GDC-046; GDC 046. CAS No. 1258292-64-6. Molecular formula: C16H13Cl2N3O2. Mole weight: 350.20. | |
| GDC-0575 | GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC50 of 1.2 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ARRY-575; RG7741. CAS No. 1196541-47-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112167. | |
| GDC-0575 | GDC-0575 is a highly-selective, potent and oral small-molecule Chk1 inhibitor (IC50 = 1.2?nM). Uses: Protein kinase inhibitors. Synonyms: ARRY-575; RG7741; GDC0575. Grade: ≥98%. CAS No. 1196541-47-5. Molecular formula: C16H20BrN5O. Mole weight: 378.27. | |
| GDC0575 monohydrochloride | GDC0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. Synonyms: GDC0575 hydrochloride; ARRY-575 hydrochloride; (R)-N-(4-(3-Aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide hydrochloride. Grade: 95%. CAS No. 1196504-54-7. Molecular formula: C16H21BrClN5O. Mole weight: 414.73. | |
| GDC-0623 | GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. Synonyms: GDC0623; GDC-0632; GDC 0632; G868; G 868; G-868. CAS No. 1168091-68-6. Molecular formula: C16H14FIN4O3. Mole weight: 456.216. | |
| GDC-0623 | GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM). Uses: Scientific research. Category: Signaling pathways. Alternative Names: RG 7421; MEK inhibitor 1. CAS No. 1168091-68-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15610. | |
| GDC-0810 (ARN-810) | GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. Synonyms: GDC0810; GDC 0810; GDC-0810; ARN810; ARN 810; ARN-810; RG6046; RG-6046; RG 6046. Grade: 98%. CAS No. 1365888-06-7. Molecular formula: C26H20ClFN2O2. Mole weight: 446.91. | |
| GDC-0834 | GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human. Synonyms: GDC-0834; GDC0834; GDC 0834. CAS No. 1133432-46-8. Molecular formula: C33H36N6O3S. Mole weight: 596.74. | |
| GDC-0834 | GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA)[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1133432-49-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15427. | |
| GDC-0837 | GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg) in a rat CIA model induced a decrease of ankle swelling and reduction of morphologic pathology in a dose-dependent manner. Synonyms: GDC-0837; GDC 0837; GDC0837. CAS No. 1133432-49-1. Molecular formula: C33H36N6O3S. Mole weight: 596.74. | |
| GDC-0853 | GDC-0853 is a Bruton's tyrosine kinase (BTK) inhibitor originated by Genentech. GDC-0853 can inhibit the activity of BTK and prevent the activation of the B-cell antigen receptor (BCR) signaling pathway. This leads to the inhibition of the growth of malignant B-cells that overexpress BTK. Phase III clinical trials for the treatment of Multiple sclerosis and Phase II clinical trials for the treatment of Chronic urticaria and Systemic lupus erythematosus are on-going. Uses: Rheumatoid arthritis; autoimmune disorders. Synonyms: Fenebrutinib; RG 7845; RG7845; GDC0853; RG-7845; GDC 0853; (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one. Grade: 98%. CAS No. 1434048-34-6. Molecular formula: C37H44N8O4. Mole weight: 664.81. | |
| GDC 0879 | GDC 0879. Group: Biochemicals. Grades: Purified. CAS No. 905281-76-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GDC-0879 | GDC-0879. Group: Biochemicals. Alternative Names: 2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-Inden-1-one Oxime. Grades: Highly Purified. CAS No. 905281-76-7. Pack Sizes: 2.5mg. Molecular Formula: C19H18N2O4, Molecular Weight: 334.37. US Biological Life Sciences. | Worldwide |
| GDC-0879 | GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases. Group: Inhibitors. Alternative Names: AR-00341677. CAS No. 905281-76-7. Pack Sizes: 2mg. Product ID: S1104. Formula: C19H18N4O2. Smiles: C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| GDC-0879 | GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(V600E) tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS-expressing tumors. Despite the involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression was observed for some KRAS-mutant tumors following GDC-0879 administration. Moreover, striking differences were noted for RAF and MEK inhibition across a panel of 130 tumor cell lines. Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity. These data suggest that GDC-0879-induced signaling changes are dependent on the point of oncogenic activation within the RAS network. Taken together, these studies increase our understanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition and have implications for therapeutic intervention in the clinic. Synonyms: GDC0879; GDC-0879; GDC 0879. CAS No. 905281-76-7. Molecular formula | |
| GDC-0879 | GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 905281-76-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50864. | |
| GDC-0917 | CUDC-427, also known as, GDC-0917, is an orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic CUDC-427 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Synonyms: GDC-0917; GDC0917; GDC 0917; CUDC-427; CUDC427; CUDC-427. Grade: 0.98. CAS No. 1446182-94-0. Molecular formula: C29H36N6O4S. Mole weight: 564.705. | |
| GDC-0927 | GDC-0927 (SRN-927) is a selective oral estrogen receptor degrader (SERD) in a phase I clinical trial for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Study shows well tolerability and clinical effect. Uses: The potential therapy of breast cancer caused by estrogen disorder. Synonyms: SRN-927; SRN 927; SRN927; GDC-0927; GDC 0927; GDC0927. CAS No. 1642297-01-5. Molecular formula: C28H28FNO4. Mole weight: 461.52. | |
| GDC-0927 Racemate | GDC-0927 Racemate is an estrogen receptor degrader, which can effectively inhibit ER-α activity with an IC50 of 0.2 nM. It is used to study ER-related diseases. Synonyms: SRN-927 Racemate; 2H-1-Benzopyran-6-ol, 2-[4-[2-[3-(fluoromethyl)-1-azetidinyl]ethoxy]phenyl]-3-(3-hydroxyphenyl)-4-methyl-. Grade: ≥95%. CAS No. 1443983-36-5. Molecular formula: C28H28FNO4. Mole weight: 461.52. | |
Our database is helping our users find suppliers everyday.
